Intismeran autogene has delivered the first positive phase 3 for an individualised neoantigen therapy, while autogene cevumeran's colorectal trial was…
irAEs often track with response to checkpoint inhibitors, but immortal time bias inflates the link. Here is what the evidence…
Beyond T cell engagers: how receptor-targeting and PD-1 x VEGF bispecific antibodies are selected, what their toxicity looks like, and…
The FDA's 2024 LDT rule was vacated in March 2025 and formally rescinded in September 2025. Here is where US…
How biomarker, CDx, CRO and diagnostics teams should read late-stage clinical readouts in the June data season: pre-specified vs exploratory…
Claudin 18.2 has a 75% companion diagnostic cut-off for zolbetuximab while its lead ADC succeeded at 25%, and B7-H3 ADCs…
Profiles of 26 Boston and Cambridge biotech companies in oncology, immunotherapy, cell therapy and diagnostics, with lead programmes, stage and…
Whole slide imaging is cleared for primary diagnosis, but quantitative biomarker scoring is a different validation problem. Here is where…
A practical B2B event marketing playbook for diagnostics, tools, CRO and platform companies: choosing event formats, setting pipeline objectives, pre-,…
How oncology biomarker tests are adopted in England: Genomic Laboratory Hubs, the National Genomic Test Directory, how PD-L1 and other…
300+ senior leaders. Two streams. One agenda: advancing precision oncology.